ArticleBiomarker research2026
Evaluation of Epstein-Barr virus DNA methylation and load in saliva in the management of individuals at high risk of nasopharyngeal carcinoma.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe current Epstein–Barr virus (EBV) antibody-based screening strategy for nasopharyngeal carcinoma (NPC) has been used for years. However, its low positive predictive value (PPV) often leads to unnecessary diagnostic procedures. Thus, further triage strategies are needed.
methodsSaliva EBV DNA methylation and viral load were explored as noninvasive triage tools for NPC detection in this study. Saliva samples were collected from 621 NPC patients and 642 healthy controls recruited in Guangdong Province, China, between 2011 and 2014. The EBV DNA methylation and viral load were measured by real-time PCR, and the diagnostic performance was assessed for each biomarker individually and in combination using a logistic regression model. A simulation model was developed to evaluate the efficiency of a stepwise screening strategy integrating serum EBV antibody testing and saliva EBV DNA testing.
resultsCompared with the controls, EBV load was decreased while DNA methylation was increased in the saliva of NPC patients (both P < 0.0001). The area under the curve (AUC) values for saliva EBV DNA methylation and viral load in distinguishing patients from controls were 0.865 (95% CI: 0.835–0.894) and 0.594 (95% CI: 0.552–0.637), respectively. Combining both markers increased the AUC to 0.908 (95% CI: 0.868–0.947). In the high-risk group based on serum EBV antibody testing, the combination of assessments of saliva EBV DNA methylation and viral load yielded an AUC of 0.969 (95% CI: 0.945–0.993). In a modeled screening program, a stepwise approach using serum EBV antibodies followed by saliva testing for EBV DNA methylation and viral load reduced the number of endoscopic examinations needed to identify one patient with NPC by approximately 60%, increasing the PPVs to 2.40–2.63 times across populations with NPC incidence rates ranging from 10 to 200 per 100,000, compared with EBV serology-only screening.
conclusionsSaliva testing for EBV DNA methylation and viral load shows potential as a triage tool following serum EBV antibody-based screening. The feasibility of home-based self-sampling further increases its utility in the management of individuals at high risk of NPC. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.